Intarcia Therapeutics, Inc.

Durect Corporation

Indivior UK Limited

Cardinal Health Switzerland 515 Gmbh

Andrew S Luk

Guohua Chen

Catherine Manya Rohloff

Pauline C Zamora

Rupal A Ayer

Paul R Houston

Stan Lam

Gunjan H Junnarkar

Michael A DesJardin

Michael A Desjardin

Theodore L Parker

Gary Steese-Bradley

Thai Minh Nguyen

Gunjan Junnarkar

An injectable depot formulation includes a biocompatible polymer, an organic solvent combined with the biocompatible polymer to form a viscous gel, and a small molecule drug incorporated in the viscous gel such that the formulation exhibits an in vivo release profile having a Cto Cratio of less than 200 and a lag time less than 0.2.

Sustained release small molecule drug formulation

An injectable depot formulation includes a biocompatible polymer, an organic solvent combined with the biocompatible polymer to form a viscous gel, and a small molecule drug incorporated in the viscous gel such that the formulation exhibits an in vivo release profile having Cto Cratio less than 200 and lag time less than 0.2.

A nonaqueous, single-phase vehicle that is capable of suspending an active agent. The nonaqueous, single-phase vehicle includes at least one solvent and at least one polymer and is formulated to exhibit phase separation upon contact with an aqueous environment. The at least one solvent may be selected from the group consisting of benzyl benzoate, decanol, ethyl hexyl lactate, and mixtures thereof and the at least one polymer may be selected from the group consisting of a polyester, pyrrolidone, ester of an unsaturated alcohol, ether of an unsaturated alcohol, polyoxyethylenepolyoxypropylene block copolymer, and mixtures thereof. In one embodiment, the at least one solvent is benzyl benzoate and the at least one polymer is polyvinylpyrrolidone. A stable, nonaqueous suspension formulation that includes the nonaqueous, single-phase vehicle and an active agent, and a method of forming the same, are also disclosed.

Solvent/polymer solutions as suspension vehicles

Implantable medical devices may be utilized to locally delivery one or more drugs or therapeutic agents to treat a wide variety of conditions, including the treatment of the biological organism's reaction to the introduction of the implantable medical device. These therapeutic agents may be released under controlled and directional conditions from a stent so that the one or more therapeutic agents reach the correct target area, for example, the surrounding tissue.

Rapamycin reservoir eluting stent

Osmotic drug delivery devices containing suspension formulations comprising particles having active agents and nonaqueous single-phase vehicles

Growing community of inventors

Castro Valley, CA, United States of America

Andrew S Luk